News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
109–144
Matches
8031
Sources here
14
Companies here
32
Search results Stored financial headlines

Active search

8031 matching headlines

Ticker or company: ARMMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX

GSA Capital Partners LLP has acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), purchasing 62,775 shares valued at approximately $1.37 million during the second quarter. This move comes as several other institutional investors also increased their holdings in the company. Despite missing revenue …

SNDX main company
Sharemaestro market context Price below Trend Line 52 weeks +22.2% SNDX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to form a leading CNS-focused biopharmaceutical company. This tax-free merger of equals anticipates $125 million in annual cost synergies within the first year and will create a combined portfolio of 11 medicines across addiction, ADHD, depression, and …

SUPN main company
Sharemaestro market context Price below Trend Line 52 weeks +7.6% SUPN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

HYFM Looks 69.8% Undervalued on GF Value™

Hydrofarm Holdings Group Inc (HYFM) appears 69.8% undervalued based on its GF Value™ of $4.85 per share, but this is tempered by its weak financial health, ongoing losses, and declining revenue. The company reported a significant GAAP EPS loss and a 40.9% year-over-year revenue …

HYFM main company
Sharemaestro market context Price above Trend Line 52 weeks -66.4% · Next-week setup negative 39.5% HYFM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Flputnam Investment Management Co. Invests $19.93 Million in Vertex Pharmaceuticals Incorporated $VRTX

Flputnam Investment Management Co. has acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), purchasing 40,116 shares valued at approximately $19.93 million during the second quarter. Other institutional investors have also adjusted their holdings in the pharmaceutical company. Analyst ratings for VRTX are generally …

VRTX main company
Sharemaestro market context Trend signal active 52 weeks +28.0% VRTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Global Retirement Partners LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Global Retirement Partners LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) during the second quarter, purchasing 3,925 shares valued at approximately $1,950,000. Several other institutional investors also adjusted their holdings in the pharmaceutical company. Vertex Pharmaceuticals has a market capitalization of $128.36 …

VRTX main company
Sharemaestro market context Trend signal active 52 weeks +28.0% VRTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Chase Investment Counsel Corp Makes New $2.03 Million Investment in Sprouts Farmers Market, Inc. $SFM

Chase Investment Counsel Corp initiated a new position in Sprouts Farmers Market, Inc. (NASDAQ:SFM) during the second quarter, investing approximately $2.03 million by purchasing 24,000 shares. This comes as Sprouts Farmers Market reported strong Q2 earnings with EPS of $1.37 and revenue of $2.33 …

SFM main company
Sharemaestro market context Trend signal active 52 weeks -43.6% · Next-week setup positive 59.0% SFM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN

Focus Partners Advisor Solutions LLC recently invested $1.35 million in Regeneron Pharmaceuticals, acquiring 2,165 shares during the second quarter. Regeneron reported strong quarterly results, beating analyst estimates with EPS of $14.29 and revenue of $4.29 billion, marking a 16.7% year-over-year increase. Despite potential legal …

REGN main company
Sharemaestro market context Price above Trend Line 52 weeks +36.8% REGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD

Empowered Funds LLC has made a new investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), acquiring 48,982 shares valued at approximately $1.09 million. This comes as institutional investors hold 96.71% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average price target …

ACAD main company
Sharemaestro market context Trend signal active 52 weeks +9.7% · Next-week setup negative 41.7% ACAD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Bank of America Corp DE

Bank of America Corp DE significantly increased its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 84.4% in the first quarter, now holding 847,089 shares valued at $27.1 million. Despite beating revenue expectations, NewAmsterdam Pharma reported a quarterly loss that missed analyst estimates, leading …

NAMS main company
Sharemaestro market context Price below Trend Line 52 weeks +7.9% NAMS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

AMG National Trust Bank has made a new $1.22 million investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by purchasing 1,956 shares. This investment comes amidst various other hedge funds adjusting their positions in the biopharmaceutical company, which recently reported strong quarterly earnings, beating analyst estimates, …

REGN main company
Sharemaestro market context Price above Trend Line 52 weeks +36.8% REGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Cue Biopharma GAAP EPS of -$24.14 misses by $22.23, revenue of $7.88M beats by $5.78M

* Cue Biopharma press release [https://seekingalpha.com/pr/20620099-cue-biopharma-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (CUE [https://seekingalpha.com/symbol/CUE]): Q2 GAAP EPS of -$24.14 misses by $22.23. * Revenue of $7.88M (+167.1% Y/Y) beats by $5.78M. * As of June 30, 2026, the company had $17.4 million in cash and cash equivalents after incurring one-time …

CUE main company
Sharemaestro market context Trend signal active 52 weeks +38.0% · Next-week setup negative 44.6% CUE stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Dimensional Fund Advisors LP Has $239,000 Holdings in HA Sustainable Infrastructure Capital, Inc. $HASI

Dimensional Fund Advisors LP significantly reduced its stake in HA Sustainable Infrastructure Capital, Inc. (NYSE:HASI) by 87.7% in the first quarter, selling 46,209 shares and retaining 6,493 shares valued at $239,000. Despite this, institutional investors and hedge funds still own 96.14% of the stock, …

HASI main company
Sharemaestro market context Trend signal active 52 weeks +51.9% HASI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

2,486,038 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by AIGH Capital Management LLC

AIGH Capital Management LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 2,486,038 shares valued at approximately $26.7 million in the second quarter, making it their 9th largest holding. Other institutional investors like Norges Bank and Bank of New York Mellon Corp …

VRTX main company
Sharemaestro market context Trend signal active 52 weeks +28.0% VRTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

HC Wainwright Issues Pessimistic Forecast for CNTB Earnings

HC Wainwright has lowered its Q3 2026 EPS estimate for Connect Biopharma (NASDAQ: CNTB) to a loss of $0.30 per share from $0.26, despite the company recently beating Q2 expectations. The firm maintains a "Buy" rating and a $7.00 price target, aligning with the …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026

Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for Inovio Pharmaceuticals (NASDAQ:INO) to a loss of $0.20 per share, up from a previous estimate of $0.24, while maintaining a "Neutral" rating. Analyst sentiment for Inovio is generally positive, with a consensus "Moderate Buy" …

INO main company
Sharemaestro market context Price below Trend Line 52 weeks -44.4% · Next-week setup negative 43.9% INO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen has upgraded Rocket Pharmaceuticals (NASDAQ:RCKT) from a "sell" to a "hold" rating, aligning with the broader analyst consensus and an average target price of $8.57. The company's shares opened at $3.47 and have seen significant insider selling totaling $327,220 over the …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M

* Citius Pharmaceuticals press release [https://seekingalpha.com/pr/20620155-citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides] (CTXR [https://seekingalpha.com/symbol/CTXR]): Q3 GAAP EPS of -$0.34 misses by $0.09. * Revenue of $1.5M misses by $8.27M. * Cash and cash equivalents of $17.0 million as of June 30, 2026. MORE ON CITIUS PHARMACEUTICALS * Seeking Alpha’s Quant …

CTXR main company
Sharemaestro market context Price above Trend Line 52 weeks -44.0% · Next-week setup negative 40.1% CTXR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Traws Pharma GAAP EPS of -$0.16 beats by $0.06

* Traws Pharma press release [https://seekingalpha.com/pr/20620150-traws-pharma-reports-q2-2026-financial-results-and-provides-business-highlights] (TRAW [https://seekingalpha.com/symbol/TRAW]): Q2 GAAP EPS of -$0.16 beats by $0.06. * Cash and cash equivalents: As of June 30, 2026, the Company had cash and cash equivalents of $5.0 million, compared to $3.8 million as of December 31, …

TRAW main company
Sharemaestro market context Price below Trend Line 52 weeks -59.5% · Next-week setup negative 40.7% TRAW stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BIOMARIN PHARMACEUTICAL INC. : PIPER SANDLER RAISES TARGET PRICE TO $88 FROM $82

Piper Sandler has increased its target price for BioMarin Pharmaceutical Inc. (BMRN.O) from $82 to $88. This adjustment reflects an updated outlook from the analytical firm regarding the biotechnology company's valuation. The news was reported by Reuters.

BMRN main company
Sharemaestro market context Trend signal active 52 weeks +15.0% BMRN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Radiopharm Theranostics (ASX:RAD) Sets October FDA Meeting as RAD101 Moves Toward Phase 3

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the Phase 3 trial design for its imaging agent, RAD101. This comes after RAD101 achieved 93% concordance between MRI and PET imaging in its Phase 2b …

RADX main company
Sharemaestro market context Price below Trend Line 52 weeks -54.9% · Next-week setup negative 44.4% RADX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) on behalf of investors. This investigation follows Alnylam's announcement on July 30, 2026, of lowered full-year 2026 TTR product sales guidance, leading to a significant drop in its stock price. …

ALNY main company
Sharemaestro market context Price below Trend Line 52 weeks -49.7% · Next-week setup negative 43.7% ALNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Securities Fraud Investigation Into Armstrong World Industries, Inc. (AWI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into Armstrong World Industries, Inc. (AWI) following a significant drop in its stock price. The investigation stems from the company's Q4 and full-year 2025 financial results, which missed consensus estimates and revealed …

AWI main company
Sharemaestro market context Price above Trend Line 52 weeks -7.1% · Next-week setup positive 56.5% AWI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context